Claudio Dansky Ullmann - lly owned subsidiary, Takeda Pharmaceutical Company Limited

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 37 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract CT122: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients with Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube

Shannon N. Westin,Travis Sims,Karen Andreas, Eric Soliman,Manish Jain,Claudio A. Dansky Ullmann,Amir A. Jazaeri

Cancer Researchno. 8_Supplement (2023)

引用0浏览0引用

Feasibility and Preliminary Safety and Efficacy of First-in-human Intraperitoneal Delivery of MCY-M11, Anti-Human-mesothelin CAR Mrna Transfected into Peripheral Blood Mononuclear Cells, for Ovarian Cancer and Malignant Peritoneal Mesothelioma

Christina M. Annunziata,Armin Ghobadi,Eduardo J. Pennella,Julie Vanas, Charles Powell,Mira Pavelova,Cathy Wagner,Michael Kuo,Claudio Dansky Ullmann, Raffit Hassan,Premal H. Thaker

Journal of Clinical Oncology（2020）

引用7浏览0引用

Abstract CT159: A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy

Armin Ghobadi,Premal Thaker,David Weng,Julie Vanas,Irene Ekwede, Mira Pavlova,Robert Keefe,Michael Kuo,Claudio Dansky Ullmann,Raffit Hassan,Christina Annunziata

Cancer research（2019）

引用1浏览0引用

Initial Results from First-in-human Study of IPI-549, a Tumor Macrophage-Targeting Agent, Combined with Nivolumab in Advanced Solid Tumors

Ryan J. Sullivan,David S. Hong,Anthony W. Tolcher,Amita Patnaik,Geoffrey Shapiro,Bartosz Chmielowski,Antoni Ribas,Les H. Brail,Jennifer Roberts,Lucy Lee,Brenda O'Connell,Jeffrey Lorne Kutok,Suresh Mahabhashyam,Claudio Dansky Ullmann,Michael A. Postow,Jedd D. Wolchok

Journal of clinical oncology（2018）

引用54浏览0引用

Mass Balance, Routes of Excretion, and Pharmacokinetics of Investigational Oral [14C]-Alisertib (MLN8237), an Aurora A Kinase Inhibitor in Patients with Advanced Solid Tumors

Xiaofei Zhou,Sandeepraj Pusalkar,Swapan K. Chowdhury,Shawn Searle,Yuexian Li,Claudio Dansky Ullmann,Karthik Venkatakrishnan

Investigational new drugs（2018）

引用5浏览0WOS引用

Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors

Antoni Ribas,David Hong,Anthony Tolcher,Ryan Sullivan,Geoffrey Shapiro,Bartosz Chmielowski,Les Brail,Lucy Lee,Suresh Mahabhashyam,Claudio Dansky Ullmann,Michael Postow,Jedd Wolchok

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2017）

引用0浏览0引用

Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo plus Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

Taofeek Owonikoko,Kristiaan Nackaerts,Tibor Csoszi,Gyula Ostoros,Christina Baik,Claudio Dansky Ullmann,Erin Zagadailov,Emily Sheldon-Waniga,Dirk Huebner,E. Jane Leonard,David Spigel

JOURNAL OF THORACIC ONCOLOGY（2017）

引用0浏览0引用

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel As Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

Taofeek Owonikoko,Kristiaan Nackaerts,Tibor Csoszi,Gyula Ostoros,Christina Baik,Claudio Dansky Ullmann,Erin Zagadailov,Emily Sheldon-Waniga,Dirk Huebner,E Jane Leonard,David Spigel

Journal of thoracic oncology（2017）

引用23浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn